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Abstract: Endothelial cells present in tumors show different origin, phenotype, and genotype with
respect to the normal counterpart. Various mechanisms of intra-tumor vasculogenesis sustain the
complexity of tumor vasculature, which can be further modified by signals deriving from the tumor
microenvironment. As a result, resistance to anti-VEGF therapy and activation of compensatory
pathways remain a challenge in the treatment of cancer patients, revealing the need to explore
alternative strategies to the classical anti-angiogenic drugs. In this review, we will describe some
alternative strategies to inhibit tumor vascularization, including targeting of antigens and signaling
pathways overexpressed by tumor endothelial cells, the development of endothelial vaccinations, and
the use of extracellular vesicles. In addition, anti-angiogenic drugs with normalizing effects on tumor
vessels will be discussed. Finally, we will present the concept of endothelial demesenchymalization
as an alternative approach to restore normal endothelial cell phenotype.
Keywords: tumor vasculogenesis; endothelial cells; anti-angiogenic drugs; normalization; endothelial
demesenchymalization; endothelial vaccination
1. Introduction
1.1. Tumor Endothelial Cell Characterization
In 1971, Judah Folkman observed that solid tumors show a diffuse vascular network, often
hemorrhagic, and that poorly vascularized tumors were unable to grow beyond 2–3 mm [1].
These observations led Folkman to hypothesize that to grow and expand, tumors need new blood
vessels, introducing the concept of tumor angiogenesis [1]. It is now well established that, during
the early phases of tumor angiogenesis, a process called “angiogenic switch” occurs, characterized
by overexpression of pro-angiogenic factors, neoangiogenesis, and tumor cell survival [2]. Indeed,
tumor angiogenesis significantly differs from physiological angiogenesis. Tumor vessels have an
irregular aspect, are dilated and tortuous, and this chaotic organization results in the absence of distinct
venules, arterioles, and capillaries, with the formation of a leaky and hemorrhagic vascular network [3].
They have an incomplete basal membrane, with large joints and fenestrations which increase the
interstitial fluid pressure, possibly resulting in intra-tumor bleeding [4].
Tumor endothelial cells (TEC) themselves substantially differ from the normal counterpart. In 2000,
Croix et al. identified for the first time genes differentially expressed in TEC with respect to normal
endothelial cells, most of which are involved in the formation of collagen, in angiogenesis and in the
wound healing process, demonstrating that tumor endothelium is different from normal endothelium
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at a molecular level [5]. In addition, TEC can be aneuploid, express embryonic markers, and can
undergo endothelial–mesenchymal transition. Hida et al. first demonstrated that freshly isolated
TEC present structural aberrations, such as nonreciprocal translocations, missing chromosomes, and
have multiple centrosomes [6]. Functionally, TEC display an increased proliferation rate and delayed
senescence with respect to normal endothelial cells due to autocrine production of proangiogenic
factors [7] and are resistant to classical anti-angiogenic drugs [8,9].
1.2. Tumor Endothelial Cell Origin
The evidence that tumor vessels differ from normal vessels, both, genotypically and functionally
suggests that tumor vasculature could either be modified by factors deriving from the tumor
microenvironment or directly originate by intra-tumor vasculogenesis as alternative mechanisms other
than the recruitment from pre-existing vessels in adjacent tissues [10]. The strategies of intra-tumor
vasculogenesis are shown in Figure 1.
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Figure 1. Alternative strategies of tumor vascularization. Tumor vessels may be generated by
intra-tumor vasculogenesis as an alternative to endothelial cell recruitment from adjacent vessels.
TEC may originate from the recruitment of bone marrow-derived cells (BMDC), such as endothelial
progenitor cells, or directly from tu or cells acquiring an endothelial phenotype in a process called
vasculogenic mimicry. Moreover, a subpopulation of cancer cells with stem features (CSCs) can directly
differentiate into tumor endothelial cells (TEC) or can reprogram normal endothelial cells by the release
of extracellular vesicles (CSC-EVs). Finally, intussusceptive microvascular growth allows the generation
of a new vessel by the split of a pre-existing one.
There are several pieces of evidence that factors secreted by tumor cells, and in primis extracellular
vesicles (EVs), may reprogram normal quiescent endothelial cells through the t ansfer of proteins and
genetic material (mRNAs, miRNAs, or proteins) [11–13]. In parallel, the intratumor vasculoge esis
might be dependent on the differentiation of normal or cancer stem cells or by endothelial mimicry f
differentiated tu or cells [10]. Bone marrow- erived cells, and i particular e dothelial progenitor
cells, actively participate to tumor growth, not only through the secretion of pro-angiogenic factors but
also through their incorporation within he vessels [14,15]. Reside t n rmal tissue stem cells were
als shown to differentiate into end thelial cells in the presence of growth factors released by the
tumor [15]. Canc r stem cells (CSC), a subpopulation of tumor cells with stem properties, can g erate
all different tumor cell types, b co ing responsibl for tumor growth and progression. Several g oup
demonstrated the ability of CSC to differentiate into endothelial cells and pe icytes and thus thei
contribution to tumor vasculog nesis [16–18].
Int. J. Mol. Sci. 2019, 20, 6180 3 of 16
Differentiated cancer cells themselves can also generate vascular structures by a process called
vasculogenic mimicry. First identified in melanoma [19], the presence of vascular mimicry has been
subsequently confirmed in a number of tumors, such as lung, breast, prostate, bladder, and renal
carcinomas and glioblastoma [20]. Finally, to rapidly adapt to the surrounding microenvironment,
tumors may generate new vessels trough intussusceptive microvascular growth. This mechanism, also
known as non-sprouting or splitting angiogenesis, is characterized by the generation of new blood
vessels by splitting an existing one [21]. The capillary network can, therefore, increase its complexity
and vascular surface, generating vessels more rapidly with a minor metabolic demand as compared to
sprouting angiogenesis.
Given the different origin, phenotype, and genotype of TEC with respect to the normal counterpart,
in the last decades, many researchers focused on the isolation of TEC from solid tumors (Table 1) [22],
to obtain an in vitro model resembling tumor angiogenesis.
Table 1. TEC isolation from solid tumors.
Tumor Type Species Year References
Glioblastoma Human 1999 Alessandri et al. [23]
Colon Human 2000 St. Croix et al. [5]
Brain tumors Human 2002 Unger et al. [24]
Renal Human 2003 Bussolati et al. [7]
Lung Mouse 2003 Allport et al. [25]
B-Cell lymphoma Human 2004 Streubel et al. [26]
Liposarcoma and melanoma Mouse 2004 Hida et al. [27]
Breast Human 2006 Grange et al. [28]
Breast Mouse 2006 Amin et al. [29]
Liver Human 2007 Wu et al. [30]
Ovary Human 2007 Buckanovitch et al. [31]Lu et al. [32]
Glossal lymphangioma Human 2010 You et al. [33]
Prostate Human 2014 Fiorio et al. [8]
1.3. Classic Anti-Angiogenic Therapies
A number of anti-angiogenic drugs have been developed and proposed to limit tumor growth
and expansion [34]. At present, the main anti-angiogenic therapies approved by the FDA are described
in Table 2 [34]. The use of anti-angiogenic drugs in clinical practice, however, only showed an initial
benefit in patients, followed by limited effectiveness and only a moderate disease-free survival [35].
This is mainly due to the expression of alternative angiogenic pathways [36,37]. Although inhibitors
of the VEGF pathway are substantially effective in reducing tumor vascularization, after treatment
discontinuation the tumor vascular network is able to re-grow, acquiring overexpression of vascular
growth factor receptors [36]. This overexpression leads the survived vessels to VEGF-independency
and, therefore, to the development of resistance [37]. In addition, anti-angiogenic treatment can lead to
the formation of a hypoxic microenvironment, which regulates the cancer stem cell population and can
contribute both to the maintenance of the tumor and to the resistance to therapies [36].
Anti-angiogenic agents, such as the monoclonal antibody (mAb) bevacizumab, only showed
significant activity when combined with cytotoxic chemotherapy [36]. Moreover, despite the success of
the dual blockade of VEGFR and PDGFR by the tyrosine kinase inhibitor (TKI) sunitinib, a combination
strategy using bevacizumab and imatinib, another inhibitor of PDGF signaling, was not effective but
rather toxic during renal cancer treatment [38]. After 10 years of approval by the FDA of the first
anti-VEGF drug, bevacizumab, resistance to anti-VEGF therapy remains a challenge in the treatment
of cancer patients, revealing the need to explore alternative strategies to classical anti-angiogenic
therapies, to obtain a durable therapeutic effect. In this review, we will describe some alternative
strategies to inhibit tumor vascularization, such as the use of new mAbs, the target of alternative
signaling pathways, the vaccination with endothelial antigens, and the use of extracellular vesicles
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(Figure 2). In addition, the use of alternative anti-angiogenic drugs with normalizing effects on tumor
vessels will be described.
Table 2. Main anti-angiogenic drugs for solid tumors treatment.
Drug Name Type Targets Tumor Type Combined Therapy
Bevacizumab mAb VEGF-A
Colorectal, lung, glioblastoma,
renal cell carcinoma, breast, brain,





Sorafenib TKI VEGFR1/2/3,PDGFR, c-kit
Renal cell carcinoma, liver,
thyroid, desmoid tumors





Pazopanib TKI VEGFR1/2/3, PDGFR, c-kit, FGFR Renal cell carcinoma and softtissue sarcoma









Cabozantinib TKI c-MET, VEGFR2, AXL, Ret Medullary thyroid cancer andrenal cell carcinoma
Nintedanib TKI VEGFR1/2/3, PDGFR, FLT-3 Idiopatic pulmonary fibrosis, lungcancer Docetaxel
Levantinib TKI VEGFR1/2/3, PDGFR, FGFR, Ret,c-Kit
Thyroid cancer and renal cell
carcinoma Everolimus
Vandetanib TKI VEGFR1/2/3, EGFR, and Ret Medullary thyroid cancer
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Figure 2. Alternative strategies to target tumor vascularization. Approaches to overcome the
resistance to classical anti-angiogenic agents may involve the target of different molecules, such as
calcium-permeable channels (Ca2+ channels), the transcription factor ERG, endoglin (CD105), or
angiopoietin (Ang-2). TEC could also be targeted by stem ell-derived extracellular vesicles with
anti-angiog nic effect (anti-angiogenic EVs), or by a specific multi-targeted cytotoxic immune response
driven by anti-angiogenic vaccination. The irregular vascular network could be targeted by new
normalizing agents, such as Sema 3. Finally, endothelial–mesenchymal transition (EndoMT), involving
the downregulation of angiogenic molecules, represents an additional strategy for anti-angiogenic
therapy resistance. Vascular detransformation represents, therefore, a novel strategy to block tumor
abnormal vascularization.
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2. Alternative Molecular Targets
2.1. Alternative Anti-Angiogenic Antibodies
The therapeutic use of classical anti-angiogenic drugs, as the anti-VEGF Ab bevacizumab,
lacked the expected results observed in experimental models [35]. As mentioned earlier, anti-VEGF
therapy-resistant tumors increase the expression of molecules that activate alternative angiogenic
pathways [36,37,39], they can represent a new target of antibody-mediated therapies. For example,
Abs against anti-angiopoietin-2 (like nesvacumab, AMG780, MEI3617, and vanucizumab), and Abs
anti-integrin αvβ3 have been successfully tested in phase I/II study [40,41]. Another example of an
antibody targeting alternative angiogenic pathways is MP0250, a genetically engineered designed
ankyrin repeat protein (DARPin®) that specifically binds to VEGF-A, hepatocyte growth factor (HGF),
and human serum albumin (HSA) [42,43]. The antibody is currently being studied in phase I and II
clinical trials on multiple myeloma relapses (NIH N. NCT03136653) [44] on EGFR-mutated non-small
cell lung cancer (NIH N. NCT03418532) and on other neoplasms (NIH N. NCT02194426). With
its target specificities, MP0250 may thus help to overcome the resistance due to single targeting
mAbs. Moreover, transforming growth factor (TGF-β) pathway has been found over-expressed
after anti-VEGF therapy [45], suggesting that it might play an important role in the acquisition of
therapy resistance. Endoglin (CD105) is a cell membrane glycoprotein overexpressed on proliferating
endothelial cells that binds several factors of the TGF-β superfamily, suggesting that activation of
this pathway may be responsible for tumor VEGF-independency [46]. In 1995, CD105 was described
as a receptor overexpressed in tumor vasculature [47] and, more recently, it has been shown that
high CD105 expression on vessels is correlated with poor prognosis in many solid tumors, such as
kidney [48], prostate [49], and ovarian cancer [50]. CD105 was also described as a marker of CSC in
renal cell carcinoma [16]. TRC105 (carotuximab) is a novel, clinical-stage antibody against CD105, that
inhibits tumor vessel formation through the blockade of CD105. In a recent study, the TRC105 effect on
both TEC lines and CSC-TEC was described [51]. In particular, TRC105 alone affected the ability of
TEC and CSC-TEC to organize in tubular structures [51]. Moreover, TRC105 increased the effect of the
tyrosine kinase inhibitor Sunitinib in inhibiting tumor endothelial proliferation, survival, and new
vessel formation [51]. Taken together, these findings indicate that the combined inhibition of VEGF
and TGF-β pathways may have potential use in renal carcinoma therapy. Indeed, TRC105 is currently
being studied in phase III clinical trial in combination with pazopanib for the treatment of advanced
angiosarcoma [52] and in multiple phase I and II clinical trials combination with VEGF inhibitors for
the treatment of different solid tumors. For example, clinical trials in phase I and II are testing the
efficacy of TRC105 in combination with bevacizumab in refractory gestational trophoblastic neoplasia
and choriocarcinoma (NIH N. NCT02396511) [53], metastatic renal cancer (NIH N. NCT01727089),
and glioblastoma (NIH N. NCT01564914 and NCT01648348). Other studies tested the combination of
TRC105 with tyrosine kinase inhibitors, such as Axitinib in renal cell carcinoma (NIH N. NCT01806064),
and sorafenib in hepatocellular carcinoma [54]. Encouraging evidence of activity to date was observed,
and the study is now continuing to recruit in the phase II stage to confirm the activity of the combination
therapy [54].
2.2. Ca2+-Permeable Channels
Accumulating evidence demonstrates that the development of several cancers involves altered
Ca2+ homeostasis and aberrant ion channel expression [55,56]. This is not surprising considering the
multifaceted role of Ca2+ as an ubiquitous second messenger, which is involved in the tuning of multiple
fundamental cellular functions [57]. Indeed, ion channels represent good potential pharmacological
targets due to their location on the plasma membrane, where they can be easily accessed by drugs.
As the first reports suggesting a role for ion channels in cancer progression, the field has undergone
an exponential development giving rise to a large consensus in the scientific community to include
“channelopathy” among the causal factors in cancer development [58,59]. In particular, it has been
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clearly established a key role for Ca2+-permeable channels in tumor vascularization both in vitro and
in vivo [60–63]. Many pro-angiogenic growth factors, as well as chemokines, trigger Ca2+ signals
directly involved in the angiogenic switch by mediating endothelial cells proliferation, migration, and
sprouting [64–67].
Among Ca2+-permeable channels, transient receptor potential (TRP) superfamily has been deeply
investigated for their functions in endothelial cells where they emerged as important factors contributing
to several key vascular processes, such as vascular tone, permeability, and cell migration [68–70].
In addition, different TRP channels have been described as mediators of VEGF-mediated Ca2+
signals [71,72]. As previously stated, TEC significantly differ from healthy endothelial cells, showing
aberrant phenotypes and physiology. It is, therefore, expected that Ca2+ homeostasis is also severely
altered in TEC; indeed, Ca2+ signals mediated by different growth factors, such as VEGF or ATP and
their downstream second messengers (arachidonic acid, nitric oxide, hydrogen sulfide, and cyclic
AMP) are drastically remodeled in TEC where they play key roles in cell migration as compared
to healthy endothelial cells [73–77]. Intriguingly, recent studies reported that TRP channels are
differentially expressed in TEC. In particular, TRPV4 has been shown to exert a proangiogenic role
on TEC by promoting cell migration and normalization [78,79]. On the contrary, TRPM8 exerts a
protective role in endothelium by inhibiting cell migration via a Rap1/βintegrin mechanism [80].
Comparative TRP expression profile has been recently performed on prostate cancer TEC (PTEC) and
their heathy counterpart, as well as on other TEC and endothelial cells. Interestingly, TRPA1, TRPV2,
and TRPC3 are overexpressed in PTEC. TRPA1 showed a clear proangiogenic role by promoting an
increase in intracellular [Ca2+] and consequent endothelial cells migration in vitro as well as sprouting
angiogenesis in the retina in vivo model [81].
2.3. ERG
ERG (ETS related gene) is part of the E-26 transformation specific (ETS) family of transcription
factors, and it was first discovered in 1987 by Reddy et al. in human colorectal carcinoma cells [82].
These factors function as either transcription activators or repressors, depending on the target gene or
on the post-transcriptional modification required [83]. From the embryonic developmental stage, ERG
is widely expressed in a variety of mesodermic tissues, and in particular in the endothelium, where
it‘s highly expressed in the endothelial cells of the majority of adult tissues [83]. In endothelial cells,
ERG plays a key role in the regulation of endothelial homeostasis by influencing numerous biological
processes, such as vasculogenesis, angiogenesis, junction stability, cell migration, and survival [83].
In fact, ERG has been shown to act as a controller of the balance between pro- and anti-angiogenic
processes, by regulating the expression of key genes like VEGFR1, VEGFR2, FZDL4, and EGF-like
protein 7 [83]. Furthermore, in vitro studies have shown that ERG is essential for endothelial tube
formation [84]. For instance, ERG inhibition studies in human endothelial cells revealed a lowered
expression of the adhesion molecule VE-cadherin that resulted in the loss of cell–cell contacts, cell
death, and, therefore, malformation of endothelial tubes [84]. These results were confirmed in vivo,
whereby a postnatal deletion of ERG in inducible endothelial-specific ERG knockout mice led to
defective angiogenesis in the retina, therefore confirming the crucial role of ERG in the regulation of
angiogenesis [84,85].
Many studies reported the involvement of abnormal ectopic expression of ERG fusion proteins
in many cancer types [86–88], however, limited studies reported the role of ERG in the regulation
of tumor neovascularization. For instance, Nagai et al. in a mouse xenograft B16F0 tumor model,
which depends on angiogenesis for growth, observed that knocking out endothelial ERG significantly
reduced the size of melanoma tumors, and significantly reduced tumor blood vessel density and
pericyte coverage compared to controls [89]. This study, therefore, confirms that ERG could play an
essential role in tumor angiogenesis and growth and that downregulation of ERG expression could be
an effective strategy towards developing new anticancer therapies.
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As ERG is largely involved in the biology of cancer, it can be considered as a potential new
target for cancer therapies itself. Indeed, ERG is one of the most overexpressed oncogenes in
prostate cancer, where a chromosomal translocation results in the fusion of the promoter region of
androgen-regulated transmembrane protease serine 2 (TMPRSS2) with the DNA-binding domain of
ERG [86]. TMPRSS2-ERG expression leads to the upregulation of the histone deacetylase 1 (HDAC)
gene and the downregulation of its target genes. A therapy based on the inhibition of HDAC can be,
therefore, effective against prostate cancer development. The HDAC inhibitors can indeed reduce
cancer growth by inducing apoptosis of ERG positive prostate cancer cells [88]. Moreover, the
development of YK-4-279, a small molecule inhibitor of ETS factors, reduced invasion, motility, and
metastasis of ERG positive cells in prostate cancer [90].
The ERG DNA-binding activity can also be targeted by modulators, such as DB1255, which
prevents ERG DNA binding [91]. Finally, the degradation of ERG by targeting an ubiquitin-specific
peptidase 9, resulted in prostate tumor growth inhibition, both, in vitro and in vivo [92]. Altogether,
these therapeutic approaches, developed at present as anti-tumor strategies, might also influence
tumor angiogenesis in view of its upregulation in TEC.
3. Extracellular Vesicles
Extracellular vesicles (EVs) are bio-active particles delimited by a lipid bilayer, secreted by a wide
variety of cells, nowadays emerging as one of the main effectors of intercellular communication [93].
Depending on the cell source, EVs have been shown to exert multiple effects on specific cell targets by
modifying their function and phenotype [93].
The clinical use of EVs for the treatment of cancer is currently under evaluation, being these
bioactive molecules an efficient tool to allow the delivery of therapeutic cargos to neoplastic cells [94].
In oncology, the use of EVs has been proposed not only as a biological carrier for anti-tumor drugs but
also as an immunomodulator and tumor vaccination [95].
Among the possible EV sources, EVs isolated from stem cells are one of the most studied
as an anticancer strategy [96]. However, few studies investigated their direct effects on tumor
angiogenesis [97–99]. Lee et al. showed that EVs isolated from mesenchymal stem cells (MSC) were
able to inhibit tumor growth and angiogenesis in a murine model of breast cancer, by downregulating
VEGF production in breast cancer cells [98]. On the other hand, EVs isolated from cardiosphere-derived
cells were able to inhibit tumor angiogenesis in a murine model of fibrosarcoma [99].
More recently, Lopatina et al. showed that EVs derived from human liver stem cells (HLSC)
exhibit a direct anti-angiogenic effect on tumor-derived endothelial cells isolated from human renal
carcinoma [97]. Treatment of renal tumor endothelial cells with HLSC-EVs in vitro inhibited the
angiogenic and migration properties of TEC in a dose-dependent manner. The inhibitory effects on
angiogenesis were mainly attributed to a down-regulation of different proangiogenic genes, targets of
specific miRNAs enriched in HLSC-EVs. In addition, the anti-angiogenic activity of HLSC-EVs has been
observed in vivo in a model of tumor angiogenesis in SCID mice. HLSC-EVs treated tumor endothelial
cells showed a limited ability to connect with murine vasculature, and treatment of pre-existent tumor
vessels with HLSC-EVs reduced vessel density [97].
These studies reveal a complex effect of EVs on tumor vascularization, which may result from the
modulation of multiple targets on different tumor cell types, including a direct effect on TEC and an
indirect one on tumor cells.
4. Anti-Angiogenic Vaccination
Cancer vaccines are emerging as one of the most promising tools for tumor eradication. Recently,
new vaccination strategies against TEC, rather than against cancer cells, have been proposed [100].
Being TEC phenotypically and genotypically different from a normal endothelium [22], anti-angiogenic
vaccination would theoretically target the activated tumor endothelium only, without affecting
other angiogenic processes involving normal endothelial cells. On the other hand, targeting one
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specific molecule could activate compensatory angiogenic pathways and resistance mechanisms, that
could be overcome by the combination with tumor immunotherapy or chemotherapy, or with other
endothelial-cell vaccines.
Vaccination protocols involve the use of different vaccine types, such as DNA or peptide vaccines,
or directly the injection of blocking antibodies against different immunogenic epitopes of proteins
overexpressed by TEC [98–102]. However, both in preclinical and in clinical studies, the efficacy and
the observed adverse events were variable, according to vaccine type, route of administration and to
the adjuvant choice [98–102]. At present, different anti-angiogenic vaccination protocols, involving the
use of peptide-based vaccines, are undergoing clinical trials, as summarized in Table 3 [101–108].
Preclinical studies involving the development of an immune response against different antigens
overexpressed by TEC, such as bFGF, angiomotin, endoglin, Robo4, PDGFRβ, Tie-2, and tumor
endothelial markers (TEM1 and TEM8) show that endothelial vaccination successfully reduces
tumor growth in different tumor models, both in vitro and in vivo [100]. However, TEC genetic
instability, together with the activation of compensatory pathways, may lead to an incomplete
response to vaccination therapies against specific targets. Therefore, further clinical studies using
whole endothelial [106] or placental cells [107] to induce a polyvalent immune response are currently
under evaluation.
Table 3. Main anti-angiogenic vaccination approaches currently undergoing clinical trials.
Antigens Vaccine Type Tumor Type Phase REF/NIH N.




I Miyazawa 2010 [101]
VEGFR1-1084 and
VEGFR2-169 peptides I/II NCT00655785
VEGFR1-A2-770 peptide I/II NCT00683085
VEGFR2-169 peptide
Advanced solid tumors
I Okamoto 2012 [102]
VEGFR1-1084 peptide I Hayashi 2013 [103]
VEGFR2, VEGFR1, URLC10,
TTK, CDCA1 multipeptide Non small cell lung cancer I Suzuki 2013 [104]
Survivin
hTERT/survivin/CMV
multipeptide Breast cancer I NCT01660529
Survivin long peptide Neuroendocrine tumors I NCT03879694
Salmonella-based Survivin





Non-small cell lung cancer




Non-small cell lung cancer,
squamous head and neck cancer I/II NCT02955290
5. Vascular Normalization and Detransformation
Vessel normalization is defined as a vascular remodeling that leads to the re-acquisition of a
normal structure and function of abnormal vessels [109].
The concept of vascular normalization as a therapeutic strategy to improve chemotherapeutic
drug delivery to tumor cells was introduced in 1996 when Yuan et al. observed an increase of
permeability in tumors treated with a VEGF-neutralizing antibody [110]. Several combinations of
classical anti-angiogenic agents and cytotoxic drugs (used in a low dose and continuous protocol, the
so-called metronomic dose) were, therefore, studied in clinical trials, but only a marginal increase
of antitumor efficacy was observed [111]. Indeed, both the dose and the temporal window of
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anti-angiogenic treatment needed to achieve a transient normalized vasculature, which allows an
adequate drug delivery to the inner tumor mass showed high variability [112,113].
Alternative strategies to achieve an increased response to anti-tumor therapies involving vascular
normalization have been proposed during the past years. Class 3 semaphorins (Sema3) are secreted
proteins that regulate cell adhesion through the signaling mediated by their receptors, composed
by the dimerization of neuropilins and plexins [114]. In endothelial cells, neuropilins were found
to bind VEGF receptors, regulating vascular development [114]. Sema3 acts as a tumor suppressor
by blocking tumor cell growth and invasion, as well as by inducing endothelial cell apoptosis [114].
In addition, Sema3A has been identified as a novel normalizing agent that can overcome the resistance
to anti-angiogenic therapies by extending the normalization window in mouse models [115].
Moreover, combined therapies involving activation of immune response and classical
anti-angiogenic agents used at a normalizing dose are under study. Several groups recently
demonstrated that the immunotherapy effect is enhanced by vessel normalization [109,113,116–119].
In particular, the immune checkpoint blockade of the programmed death receptor-1 (PD-1)/PD ligand 1
(PD-L1) pathway, combined with the VEGF-pathway blockade, can enhance both anti-tumor immunity
and a structural normalization of tumor vessels [116,118,119]. In particular, Schmittnaegel et al.
observed that blocking both angiopoietin and VEGF pathways induced tumor vessel normalization
that favored a cytotoxic immune response [118]. Allen et al. contemporarily observed that combination
therapy using blocking antibodies against VEGFR2 and PD-L1 resulted in enhanced cytotoxic activity,
together with an increased normalizing effect of VEGF blockade on tumor vasculature [119]. Clinical
trials investigating the efficacy of a combined therapy that involves the use of immune checkpoint
inhibitors and anti-angiogenic agents are currently undergoing [120].
All the anti-angiogenic therapies mentioned above, including normalizing therapies, may induce
overtime a transformation of the tumor-associated endothelial cells towards a mesenchymal profile,
called endothelial to mesenchymal transition (EndMT) [121]. In the course of EndMT, resident
endothelial cells delaminate from an organized cell layer and acquire a mesenchymal phenotype
characterized by loss of cell–cell junctions, loss of endothelial markers, the gain of mesenchymal
markers, and acquisition of invasive and migratory properties [120]. In cancer, EndMT supports
the formation of cancer-associated fibroblasts, which are known to facilitate tumor progression.
Furthermore, EndMT could also modify the endothelium abnormally, therefore, assisting tumor-cell
extravasation. Lastly, EndMT has also been reported to be induced by events such as hypoxia, high
glucose levels, as well as through the release of soluble factors in the tumor microenvironment [121].
Nagai et al. showed that EndMT can be triggered through a reduction in the expression of ERG
together with friend leukemia integration 1 transcription factor (FLI1), which has been reported to
play a pivotal role in endothelial cell homeostasis. A combined knockdown of both ERG and FLI-1
through short interfering RNA (siRNAs) in endothelial cells, caused the downregulation of endothelial
genes accompanied by a consistent upregulation of genes involved in EndMT, such as alphaSMA and
CollagenA1 in vitro [89].
It can, therefore, be concluded that dysregulation of angiogenic signaling pathways that play a
crucial role in the homeostasis of endothelial cells, can cause an imbalance in endothelial physiology,
leading to EndMT, which has been implicated in cancer progression.
As low doses of anti-angiogenic therapies from one side may induce the transformation of aberrant
vases towards normal vessels, and from the other side may favor the activation of a mesenchymal
phenotype in endothelial cells, an optimal therapy should take into consideration both vascular
normalization and endothelial de-mesenchymalization.
For example, the combination of VEGF-targeting agents and TGFβ signaling inhibition, such
as Sunitinib and TRC105 [51], as discussed above, could represent a valid therapy to block both
endothelial and mesenchymal-related pathways.
Int. J. Mol. Sci. 2019, 20, 6180 10 of 16
Funding: This study was supported by the Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.), project
IG2015 16973.
Acknowledgments: In this section you can acknowledge any support given which is not covered by the author
contribution or funding sections. This may include administrative and technical support, or donations in kind
(e.g., materials used for experiments).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Judah Folkman Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971, 262, 1182–1186.
2. De Bock, K.; Cauwenberghs, S.; Carmeliet, P. Vessel abnormalization: Another hallmark of cancer? Molecular
mechanisms and therapeutic implications. Curr. Opin. Genet. Dev. 2011, 21, 73–79. [CrossRef] [PubMed]
3. Baluk, P.; Hashizume, H.; McDonald, D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr.
Opin. Genet. Dev. 2005, 15, 102–111. [CrossRef] [PubMed]
4. De Sanctis, F.; Ugel, S.; Facciponte, J.; Facciabene, A. The dark side of tumor-associated endothelial cells.
Semin. Immunol. 2018, 35, 35–47. [CrossRef] [PubMed]
5. Miller, J.R.; Moon, R.T.; Dev, G.; Cadigan, K.M.; Nusse, R.; Cells, G.; Hart, M.J.; Santos, R.D.L.; Albert, I.N.;
Rubinfeld, B.; et al. Genes Expressed in Human Tumor Endothelium. Science 2000, 289, 1197–1202.
6. Hida, K.; Klagsbrun, M. A new perspective on tumor endothelial cells: Unexpected chromosome and
centrosome abnormalities. Cancer Res. 2005, 65, 2507–2510. [CrossRef]
7. Bussolati, B.; Deambrosis, I.; Russo, S.; Deregibus, M.C.; Camussi, G. Altered angiogenesis and survival in
human tumor-derived endothelial cells. FASEB J. 2003, 17, 1159–1161. [CrossRef]
8. Pla, A.F.; Brossa, A.; Bernardini, M.; Genova, T.; Grolez, G.; Villers, A.; Leroy, X.; Prevarskaya, N.; Gkika, D.;
Bussolati, B. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
BMC Cancer 2014, 14, 1–13.
9. Xiong, Y.Q.; Sun, H.C.; Zhang, W.; Zhu, X.D.; Zhuang, P.Y.; Zhang, J.B.; Wang, L.; Wu, W.Z.; Qin, L.X.;
Tang, Z.Y. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis
capability and drug resistance compared with normal endothelial cells. Clin. Cancer Res. 2009, 15, 4838–4846.
[CrossRef]
10. Bussolati, B.; Grange, C.; Camussi, G. Tumor exploits alternative strategies to achieve vascularization. FASEB
J. 2011, 25, 2874–2882. [CrossRef]
11. Ratajczak, J.; Wysoczynski, M.; Hayek, F.; Janowska-Wieczorek, A.; Ratajczak, M.Z. Membrane-derived
microvesicles: Important and underappreciated mediators of cell-to-cell communication. Leukemia 2006, 20,
1487–1495. [CrossRef] [PubMed]
12. Skog, J.; Würdinger, T.; van Rijn, S.; Meijer, D.H.; Gainche, L.; Curry, W.T.; Carter, B.S.; Krichevsky, A.M.;
Breakefield, X.O. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and
provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10, 1470–1476. [CrossRef] [PubMed]
13. Bergsmedh, A.; Szeles, A.; Henriksson, M.; Bratt, A.; Folkman, M.J.; Spetz, A.L.; Holmgren, L. Horizontal
transfer of oncogenes by uptake of apoptotic bodies. Proc. Natl. Acad. Sci. USA 2001, 98, 6407–6411.
[CrossRef] [PubMed]
14. Ding, Y.; Song, N.; Luo, Y. Role of bone marrow-derived cells in angiogenesis: Focus on macrophages and
pericytes. Cancer Microenviron. 2012, 5, 225–236. [CrossRef] [PubMed]
15. Bruno, S.; Bussolati, B.; Grange, C.; Collino, F.; Graziano, M.E.; Ferrando, U.; Camussi, G. CD133+ renal
progenitor cells contribute to tumor angiogenesis. Am. J. Pathol. 2006, 169, 2223–2235. [CrossRef]
16. Bussolati, B.; Bruno, S.; Grange, C.; Ferrando, U.; Camussi, G. Identification of a tumor-initiating stem cell
population in human renal carcinomas. FASEB J. 2008, 22, 3696–3705. [CrossRef]
17. Ricci-Vitiani, L.; Pallini, R.; Biffoni, M.; Todaro, M.; Invernici, G.; Cenci, T.; Maira, G.; Parati, E.A.; Stassi, G.;
Larocca, L.M.; et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.
Nature 2010, 468, 824–830. [CrossRef]
18. Bussolati, B.; Grange, C.; Sapino, A.; Camussi, G. Endothelial cell differentiation of human breast tumour
stem/progenitor cells. J. Cell. Mol. Med. 2009, 13, 309–319. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 6180 11 of 16
19. Maniotis, A.J.; Folberg, R.; Hess, A.; Seftor, E.A.; Gardner, L.M.G.; Pe’er, J.; Trent, J.M.; Meltzer, P.S.;
Hendrix, M.J.C. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic
mimicry. Am. J. Pathol. 1999, 155, 739–752. [CrossRef]
20. Ge, H.; Luo, H. Overview of advances in vasculogenic mimicry — A potential target for tumor therapy.
Cancer Manag. Res. 2018, 10, 2429–2437. [CrossRef]
21. Ribatti, D.; Djonov, V. Intussusceptive microvascular growth in tumors. Cancer Lett. 2012, 316, 126–131.
[CrossRef] [PubMed]
22. Dudley, A.C. Tumor endothelial cells. Cold Spring Harb. Perspect. Med. 2012, 2, 1–18. [CrossRef] [PubMed]
23. Alessandri, G.; Chirivi, R.G.S.; Fiorentini, S.; Dossi, R.; Bonardelli, S.; Giulini, S.M.; Zanetta, G.; Landoni, F.;
Graziotti, P.P.; Turano, A.; et al. Phenotypic and functional characteristics of tumour-derived microvascular
endothelial cells. Clin. Exp. Metastasis 1999, 17, 655–662. [CrossRef] [PubMed]
24. Unger, R.E.; Oltrogge, J.B.; Von Briesen, H.; Engelhardt, B.; Woelki, U.; Schlote, W.; Lorenz, R.; Bratzke, H.;
Kirkpatrick, C.J. Isolation and molecular characterization of brain microvascular endothelial cells from
human brain tumors. Vitr. Cell. Dev. Biol. Anim. 2002, 38, 273–281. [CrossRef]
25. Allport, J.R.; Weissleder, R. Murine Lewis lung carcinoma-derived endothelium expresses markers of
endothelial activation and requires tumor-specific extracellular matrix in vitro. Neoplasia 2003, 5, 205–217.
[CrossRef]
26. Streubel, B.; Chott, A.; Huber, D.; Exner, M.; Jäger, U.; Wagner, O.; Schwarzinger, I. Lymphoma-specific
genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N. Engl. J. Med. 2004, 351,
250–259. [CrossRef]
27. Hida, K.; Hida, Y.; Amin, D.N.; Flint, A.F.; Panigrahy, D.; Morton, C.C.; Klagsbrun, M. Tumor-associated
endothelial cells with cytogenetic abnormalities. Cancer Res. 2004, 64, 8249–8255. [CrossRef]
28. Grange, C.; Bussolati, B.; Bruno, S.; Fonsato, V.; Sapino, A.; Camussi, G. Isolation and characterization of
human breast tumor-derived endothelial cells. Oncol. Rep. 2006, 15, 381–386. [CrossRef]
29. Amin, D.N.; Hida, K.; Bielenberg, D.R.; Klagsbrun, M. Tumor endothelial cells express epidermal growth
factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res.
2006, 66, 2173–2180. [CrossRef]
30. Wu, L.Q.; Zhang, W.J.; Niu, J.X.; Ye, L.Y.; Yang, Z.H.; Grau, G.E.; Lou, J.N. Phenotypic and functional
differences between human liver cancer endothelial cells and liver sinusoidal endothelial cells. J. Vasc. Res.
2007, 45, 78–86. [CrossRef]
31. Buckanovich, R.J.; Sasaroli, D.; O’Brien-Jenkins, A.; Botbyl, J.; Hammond, R.; Katsaros, D.; Sandaltzopoulos, R.;
Liotta, L.A.; Gimotty, P.A.; Coukos, G. Tumor vascular proteins as biomarkers in ovarian cancer. J. Clin.
Oncol. 2007, 25, 852–861. [CrossRef] [PubMed]
32. Lu, C.; Bonome, T.; Li, Y.; Kamat, A.A.; Han, L.Y.; Schmandt, R.; Coleman, R.L.; Gershenson, D.M.; Jaffe, R.B.;
Birrer, M.J.; et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells
from invasive ovarian carcinoma. Cancer Res. 2007, 67, 1757–1768. [CrossRef] [PubMed]
33. You, L.; Wu, M.; Chen, Y.; Xu, G.; Wei, J.; Li, Q.; Song, A.; Zhao, L.; Li, S.; Han, Z.; et al. Isolation and
characterization of lymphatic endothelial cells from human glossal lymphangioma. Oncol. Rep. 2010, 25,
223–230.
34. Qin, S.; Li, A.; Yi, M.; Yu, S.; Zhang, M.; Wu, K. Recent advances on anti-angiogenesis receptor tyrosine
kinase inhibitors in cancer therapy. J. Hematol. Oncol. 2019, 12, 1–11. [CrossRef]
35. Jayson, G.C.; Hicklin, D.J.; Ellis, L.M. Antiangiogenic therapy-evolving view based on clinical trial results.
Nat. Rev. Clin. Oncol. 2012, 9, 297–303. [CrossRef]
36. McIntyre, A.; Harris, A.L. Metabolic and hypoxic adaptation to anti—angiogenic therapy: A target for
induced essentiality. EMBOMol. Med. 2015, 7, 368–379. [CrossRef]
37. Mancuso, M.R.; Davis, R.; Norberg, S.M.; Brien, S.O.; Sennino, B.; Nakahara, T.; Yao, V.J.; Inai, T.; Brooks, P.;
Freimark, B.; et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Investig.
2006, 116, 2610–2621. [CrossRef]
38. Hainsworth, J.D.; Spigel, D.R.; Sosman, J.A.; Burris, H.A.; Farley, C.; Cucullu, H.; Yost, K.; Hart, L.L.;
Sylvester, L.; Waterhouse, D.M.; et al. Treatment of advanced renal cell carcinoma with the combination
bevacizumab/erlotinib/imatinib: A phase I/II trial. Clin. Genitourin. Cancer 2007, 5, 427–432. [CrossRef]
39. Itatani, Y.; Kawada, K.; Yamamoto, T.; Sakai, Y. Resistance to anti-angiogenic therapy in cancer-alterations to
anti-VEGF pathway. Int. J. Mol. Sci. 2018, 19, 1232. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 6180 12 of 16
40. Kong, D.H.; Kim, M.R.; Jang, J.H.; Na, H.J.; Lee, S. A review of anti-angiogenic targets for monoclonal
antibody cancer therapy. Int. J. Mol. Sci. 2017, 18, 1786. [CrossRef]
41. McNeel, D.G.; Eickhoff, J.; Lee, F.T.; King, D.M.; Alberti, D.; Thomas, J.P.; Friedl, A.; Kolesar, J.; Marnocha, R.;
Volkman, J.; et al. Phase I trial of a monoclonal antibody specific for α v β 3 integrin (MEDI-522) in patients
with advanced malignancies, including an assessment of effect on tumor perfusion. Clin. Cancer Res. 2005,
11, 7851–7860. [CrossRef] [PubMed]
42. Binz, H.K.; Bakker, T.R.; Phillips, D.J.; Cornelius, A.; Zitt, C.; Göttler, T.; Sigrist, G.; Fiedler, U.; Ekawardhani, S.;
Dolado, I.; et al. Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug
candidate. MAbs 2017, 9, 1262–1269. [CrossRef] [PubMed]
43. Fiedler, U.; Ekawardhani, S.; Cornelius, A.; Gilboy, P.; Bakker, T.R.; Dolado, I.; Stumpp, M.T.; Dawson, K.M.
MP0250, a VEGF and HGF neutralizing DARPin® molecule shows high anti-tumor efficacy in mouse
xenograft and patient-derived tumor models. Oncotarget 2017, 8, 98371–98383. [CrossRef] [PubMed]
44. Rao, L.; Veirman, K.; de Giannico, D.; Saltarella, I.; Desantis, V.; Frassanito, M.A.; Solimando, A.G.; Ribatti, D.;
Prete, M.; Harstrick, A.; et al. Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking
DARPin® protein MP0250: A preclinical study. Oncotarget 2018, 9, 13366–13381. [CrossRef]
45. Park, S.Y.; Piao, Y.; Jeong, K.J.; Dong, J.; de Groot, J.F. Periostin (POSTN) regulates tumor resistance to
antiangiogenic therapy in glioma models. Physiol. Behav. 2016, 176, 105–111. [CrossRef]
46. Paauwe, M.; Heijkants, R.C.; Oudt, C.H.; Van Pelt, G.W.; Cui, C.; Theuer, C.P.; Hardwick, J.C.H.; Sier, C.F.M.;
Hawinkels, L.J.A.C. Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.
Oncogene 2016, 35, 4069–4079. [CrossRef]
47. Derbyshire, E.J.; Gazdar, A.F.; King, S.W.; Thorpe, P.E.; Derbyshire, E.J.; King, S.W.; Thorpe, P.E.; Gazdar, A.F.;
Vitetta, E.S.; Tazzari, P.L.; et al. Up-Regulation of Endoglin on Vascular Endothelial Cells in Human Solid
Tumors: Implications for Diagnosis and Therapy. Clin. Cancer Res. 1995, 1, 1623–1634.
48. Hu, J.; Guan, W.; Liu, P.; Dai, J.; Tang, K.; Xiao, H.; Qian, Y.; Sharrow, A.C.; Ye, Z.; Wu, L.; et al. Endoglin Is
Essential for the Maintenance of Self-Renewal and Chemoresistance in Renal Cancer Stem Cells. Stem Cell
Reports 2017, 9, 464–477. [CrossRef]
49. Madhav, A.; Andres, A.; Duong, F.; Mishra, R.; Haldar, S.; Liu, Z.; Angara, B.; Gottlieb, R.; Zumsteg, Z.S.;
Bhowmick, N.A. Antagonizing CD105 enhances radiation sensitivity in prostate cancer. Oncogene 2018, 37,
4385–4397. [CrossRef]
50. Zhang, J.; Yuan, B.; Zhang, H.; Li, H. Human epithelial ovarian cancer cells expressing cd105, cd44 and cd106
surface markers exhibit increased invasive capacity and drug resistance. Oncol. Lett. 2019, 17, 5351–5360.
[CrossRef]
51. Brossa, A.; Buono, L.; Bussolati, B. Effect of the monoclonal antibody TRC105 in combination with Sunitinib
on renal tumor derived endothelial cells. Oncotarget 2018, 9, 22680–22692. [CrossRef] [PubMed]
52. Mehta, C.R.; Liu, L.; Theuer, C. An adaptive population enrichment phase III trial of TRC105 and pazopanib
versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial). Ann. Oncol. 2019, 30,
103–108. [CrossRef] [PubMed]
53. Worley, M.J.; Elias, K.M.; Horowitz, N.S.; Quade, B.J.; Berkowitz, R.S. Durable remission for a woman with
refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from
the New England Trophoblastic Disease Center, Brigham and Women’s Hospital and Dana-Farber Cancer
Institute. Gynecol. Oncol. 2018, 148, 5–11. [CrossRef] [PubMed]
54. Duffy, A.G.; Ma, C.; Ulahannan, S.V.; Rahma, O.E.; Makarova-Rusher, O.; Cao, L.; Yu, Y.; Kleiner, D.E.;
Trepel, J.B.; Lee, M.-J.; et al. Phase I and preliminary Phase II study of TRC105 in combination with Sorafenib
in Hepatocellular Carcinoma. Clin. Cancer Res. 2017, 23, 4633–4641. [CrossRef]
55. Iamshanova, O.; Fiorio Pla, A.; Prevarskaya, N. Molecular mechanisms of tumour invasion: Regulation by
calcium signals. J. Physiol. 2017, 595, 3063–3075. [CrossRef]
56. Monteith, G.R.; Prevarskaya, N.; Roberts-Thomson, S.J. The calcium–cancer signalling nexus. Nat. Rev.
Cancer 2017, 17, 367–380. [CrossRef]
57. Berridge, M.J.; Bootman, M.D.; Roderick, H.L. Calcium signalling: Dynamics, homeostasis and remodelling.
Nat. Rev. Mol. Cell Biol. 2003, 4, 517–529. [CrossRef]
58. Munaron, L.; Arcangeli, A. Editorial: Ion fluxes and cancer. Recent Pat. Anticancer Drug Discov. 2013, 8, 1–3.
[CrossRef]
Int. J. Mol. Sci. 2019, 20, 6180 13 of 16
59. Prevarskaya, N.; Skryma, R.; Shuba, Y. Ion Channels in Cancer: Are Cancer Hallmarks Oncochannelopathies?
Physiol. Rev. 2018, 98, 559–621. [CrossRef]
60. Munaron, L.; Genova, T.; Avanzato, D.; Antoniotti, S.; Pla, A.F. Targeting Calcium Channels to Block Tumor
Vascularization. Recent Pat. Anticancer. Drug Discov. 2013, 8, 27–37. [CrossRef]
61. Moccia, F.; Negri, S.; Shekha, M.; Faris, P.; Guerra, G. Guerra Endothelial Ca2+ Signaling, Angiogenesis and
Vasculogenesis: Just What It Takes to Make a Blood Vessel. Int. J. Mol. Sci. 2019, 20, 3962. [CrossRef]
62. Farfariello, V.; Iamshanova, O.; Germain, E.; Fliniaux, I.; Prevarskaya, N. Calcium homeostasis in cancer: A
focus on senescence. Biochim. Biophys. Acta 2015, 1853, 1974–1979. [CrossRef] [PubMed]
63. Yokota, Y.; Nakajima, H.; Wakayama, Y.; Muto, A.; Kawakami, K.; Fukuhara, S.; Mochizuki, N. Endothelial
Ca2+ oscillations reflect VEGFR signaling-regulated angiogenic capacity in vivo. Elife 2015, 4, 1–26. [CrossRef]
[PubMed]
64. Dragoni, S.; Laforenza, U.; Bonetti, E.; Lodola, F.; Bottino, C.; Berra-Romani, R.; Carlo Bongio, G.; Cinelli, M.P.;
Guerra, G.; Pedrazzoli, P.; et al. Vascular endothelial growth factor stimulates endothelial colony forming
cells proliferation and tubulogenesis by inducing oscillations in intracellular Ca2+ concentration. Stem Cells
2011, 29, 1898–1907. [CrossRef] [PubMed]
65. Dragoni, S.; Reforgiato, M.; Zuccolo, E.; Poletto, V.; Lodola, F.; Ruffinatti, F.A.; Bonetti, E.; Guerra, G.;
Barosi, G.; Rosti, V.; et al. Dysregulation of VEGF-induced proangiogenic Ca2+ oscillations in primary
myelofibrosis-derived endothelial colony-forming cells. Exp. Hematol. 2015, 43, 1019–1030. [CrossRef]
[PubMed]
66. Noren, D.P.; Chou, W.H.; Lee, S.H.; Qutub, A.A.; Warmflash, A.; Wagner, D.S.; Popel, A.S.; Levchenko, A.
Endothelial cells decode VEGF-mediated Ca2+ signaling patterns to produce distinct functional responses.
Sci. Signal. 2016, 9, 1–21. [CrossRef] [PubMed]
67. Savage, A.M.; Kurusamy, S.; Chen, Y.; Jiang, Z.; Chhabria, K.; MacDonald, R.B.; Kim, H.R.; Wilson, H.L.; van
Eeden, F.J.M.; Armesilla, A.L.; et al. Tmem33 is essential for VEGF-mediated endothelial calcium oscillations
and angiogenesis. Nat. Commun. 2019, 10. [CrossRef]
68. Nilius, B.; Droogmans, G. Ion channels and their functional role in vascular endothelium. Physiol. Rev. 2001,
81, 1415–1459. [CrossRef]
69. Thakore, P.; Earley, S. Transient Receptor Potential Channels and Endothelial Cell Calcium Signaling. Compr.
Physiol. 2019, 9, 1249–1277.
70. Smani, T.; Gómez, L.J.; Regodon, S.; Woodard, G.E.; Siegfried, G.; Khatib, A.-M.; Rosado, J.A. TRP Channels
in Angiogenesis and Other Endothelial Functions. Front. Physiol. 2018, 9, 1731. [CrossRef]
71. Pocock, T.M.; Foster, R.R.; Bates, D.O. Evidence of a role for TRPC channels in VEGF-mediated increased
vascular permeability in vivo. Am. J. Physiol. Heart Circ. Physiol. 2004, 286, H1015–H1026. [CrossRef]
[PubMed]
72. Cheng, H.-W.; James, A.F.; Foster, R.R.; Hancox, J.C.; Bates, D.O. VEGF activates receptor-operated cation
channels in human microvascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 1768–1776.
[CrossRef] [PubMed]
73. Avanzato, D.; Genova, T.; Fiorio Pla, A.; Bernardini, M.; Bianco, S.; Bussolati, B.; Mancardi, D.; Giraudo, E.;
Maione, F.; Cassoni, P.; et al. Activation of P2X7 and P2Y11 purinergic receptors inhibits migration and
normalizes tumor-derived endothelial cells via cAMP signaling. Sci. Rep. 2016, 6, 32602. [CrossRef]
[PubMed]
74. Fiorio Pla, A.; Grange, C.; Antoniotti, S.; Tomatis, C.; Merlino, A.; Bussolati, B.; Munaron, L. Arachidonic
acid-induced Ca2+ entry is involved in early steps of tumor angiogenesis. Mol. Cancer Res. 2008, 6, 535–545.
[PubMed]
75. Fiorio Pla, A.; Genova, T.; Pupo, E.; Tomatis, C.; Genazzani, A.; Zaninetti, R.; Munaron, L. Multiple roles
of protein kinase a in arachidonic acid-mediated Ca2+ entry and tumor-derived human endothelial cell
migration. Mol. Cancer Res. 2010, 8, 1466–1476. [CrossRef] [PubMed]
76. Pupo, E.; Pla, A.F.; Avanzato, D.; Moccia, F.; Cruz, J.-E.E.A.; Tanzi, F.; Merlino, A.; Mancardi, D.; Munaron, L.
Hydrogen sulfide promotes calcium signals and migration in tumor-derived endothelial cells. Free Radic.
Biol. Med. 2011, 51, 1765–1773. [CrossRef]
77. Scarpellino, G.; Genova, T.; Avanzato, D.; Bernardini, M.; Bianco, S.; Petrillo, S.; Tolosano, E.; de Vieira, J.R.A.;
Bussolati, B.; Pla, A.F.; et al. Purinergic Calcium Signals in Tumor-Derived Endothelium. Cancers 2019, 11,
766. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 6180 14 of 16
78. Adapala, R.K.; Thoppil, R.J.; Ghosh, K.; Cappelli, H.C.; Dudley, A.C.; Paruchuri, S.; Keshamouni, V.;
Klagsbrun, M.; Meszaros, J.G.; Chilian, W.M.; et al. Activation of mechanosensitive ion channel TRPV4
normalizes tumor vasculature and improves cancer therapy. Oncogene 2015, 1–9. [CrossRef]
79. Fiorio Pla, A.; Ong, H.L.; Cheng, K.T.; Brossa, A.; Bussolati, B.; Lockwich, T.; Paria, B.; Munaron, L.;
Ambudkar, I.S. TRPV4 mediates tumor-derived endothelial cell migration via arachidonic acid-activated
actin remodeling. Oncogene 2012, 31, 200–212. [CrossRef]
80. Genova, T.; Grolez, G.P.; Camillo, C.; Bernardini, M.; Bokhobza, A.; Richard, E.; Scianna, M.; Lemonnier, L.;
Valdembri, D.; Munaron, L.; et al. TRPM8 inhibits endothelial cell migration via a nonchannel function by
trapping the small GTPase Rap1. J. Cell Biol. 2017, 216, 2107–2130. [CrossRef]
81. Bernardini, M.; Brossa, A.; Chinigo, G.; Grolez, G.P.; Trimaglio, G.; Allart, L.; Hulot, A.; Marot, G.; Genova, T.;
Joshi, A.; et al. Transient Receptor Potential Channel Expression Signatures in Tumor-Derived Endothelial
Cells: Functional Roles in Prostate Cancer Angiogenesis. Cancers. 2019, 11, 956. [CrossRef] [PubMed]
82. Reddy, E.S.P.; Rao, V.N.; Papas, T.S. The erg gene: A human gene related to the ets oncogene. Proc. Natl.
Acad. Sci. USA 1987, 84, 6131–6135. [CrossRef] [PubMed]
83. Shah, A.V.; Birdsey, G.M.; Randi, A.M. Regulation of endothelial homeostasis, vascular development and
angiogenesis by the transcription factor ERG. Vascul. Pharmacol. 2016, 86, 3–13. [CrossRef] [PubMed]
84. Birdsey, G.M.; Dryden, N.H.; Amsellem, V.; Gebhardt, F.; Sahnan, K.; Haskard, D.O.; Dejana, E.; Mason, J.C.;
Randi, A.M. Transcription factor erg regulates angiogenesis and endothelial apoptosis through VE-cadherin.
Blood 2008, 111, 3498–3506. [CrossRef] [PubMed]
85. Birdsey, G.M.; Shah, A.V.; Dufton, N.; Reynolds, L.E.; Almagro, L.O.; Yang, Y.; Aspalter, I.M.; Khan, S.T.;
Mason, J.C.; Dejana, E.; et al. The endothelial transcription factor erg promotes vascular stability and growth
through Wnt/β-catenin signaling. Dev. Cell 2015, 32, 82–96. [CrossRef] [PubMed]
86. Adamo, P.; Ladomery, M.R. The oncogene ERG: A key factor in prostate cancer. Oncogene 2016, 35, 403–414.
[CrossRef]
87. Brenner, J.C.; Ateeq, B.; Chinnaiyan, A.M.; Yocum, A.K.; Cao, Q.; Asangani, I.A.; Patel, S.; Wang, X.; Liang, H.;
Yu, J.; et al. Mechanistic Rationale for Inhibition of Poly ( ADP-Ribose ) Polymerase in ETS Gene Fusion-
Positive Prostate Cancer. Cancer Cell. 2011, 23, 664–678.
88. Björkman, M.; Iljin, K.; Halonen, P.; Sara, H.; Kaivanto, E.; Nees, M.; Kallioniemi, O.P. Defining the molecular
action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int. J.
Cancer 2008, 123, 2774–2781. [CrossRef]
89. Nagai, N.; Ohguchi, H.; Nakaki, R.; Matsumura, Y.; Kanki, Y.; Sakai, J.; Aburatani, H.; Minami, T.
Downregulation of ERG and FLI1 expression in endothelial cells triggers endothelial-to-mesenchymal
transition. PLoS Genet. 2018, 14, 1007826. [CrossRef]
90. Rahim, S.; Beauchamp, E.M.; Kong, Y.; Brown, M.L.; Toretsky, J.A.; Üren, A. YK-4-279 inhibits ERG and ETV1
mediated prostate cancer cell invasion. PLoS ONE 2011, 6, e19343. [CrossRef]
91. Nhili, R.; Peixoto, P.; Depauw, S.; Flajollet, S.; Dezitter, X.; Munde, M.M.; Ismail, M.A.; Kumar, A.; Farahat, A.A.;
Stephens, C.E.; et al. Targeting the DNA-binding activity of the human ERG transcription factor using new
heterocyclic dithiophene diamidines. Nucleic Acids Res. 2013, 41, 125–138. [CrossRef] [PubMed]
92. Wang, S.; Kollipara, R.K.; Srivastava, N.; Li, R.; Ravindranathan, P.; Hernandez, E.; Freeman, E.;
Humphries, C.G.; Kapur, P.; Lotan, Y.; et al. Ablation of the oncogenic transcription factor ERG by
deubiquitinase inhibition in prostate cancer. Proc. Natl. Acad. Sci. USA 2014, 111, 4251–4256. [CrossRef]
[PubMed]
93. El Andaloussi, S.; Mäger, I.; Breakefield, X.O.; Wood, M.J.A. Extracellular vesicles: Biology and emerging
therapeutic opportunities. Nat. Rev. Drug Discov. 2013, 12, 347–357. [CrossRef] [PubMed]
94. Khawar, M.B.; Abbasi, M.H.; Siddique, Z.; Arif, A.; Sheikh, N. An Update on Novel Therapeutic Warfronts of
Extracellular Vesicles (EVs) in Cancer Treatment: Where We Are Standing Right Now and Where to Go in
the Future. Oxid. Med. Cell. Longev. 2019, 2019, 1–21. [CrossRef] [PubMed]
95. Sil, S.; Dagur, R.S.; Liao, K.; Peeples, E.S.; Hu, G.; Periyasamy, P.; Buch, S. Strategies for the use of Extracellular
Vesicles for the Delivery of Therapeutics. J. Neuroimmune Pharmacol. 2019, 1–21. [CrossRef] [PubMed]
96. Brossa, A.; Fonsato, V.; Bussolati, B. Anti-tumor activity of stem cell-derived extracellular vesicles. Oncotarget
2019, 10, 1872–1873. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 6180 15 of 16
97. Lopatina, T.; Grange, C.; Fonsato, V.; Tapparo, M.; Brossa, A.; Fallo, S.; Pitino, A.; Herrera-Sanchez, M.B.;
Kholia, S.; Camussi, G.; et al. Extracellular vesicles from human liver stem cells inhibit tumor angiogenesis.
Int. J. Cancer 2019, 144, 322–333. [CrossRef]
98. Lee, J.K.; Park, S.R.; Jung, B.K.; Jeon, Y.K.; Lee, Y.S.; Kim, M.K.; Kim, Y.G.; Jang, J.Y.; Kim, C.W. Exosomes
derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast
cancer cells. PLoS ONE 2013, 8, 84256. [CrossRef]
99. Grigorian-Shamagian, L.; Fereydooni, S.; Liu, W.; Echavez, A.; Marbán, E. Harnessing the heart’s resistance to
malignant tumors: Cardiacderived extracellular vesicles decrease fibrosarcoma growth and leukemia-related
mortality in rodents. Oncotarget 2017, 8, 99624–99636. [CrossRef]
100. Wagner, S.C.; Ichim, T.E.; Ma, H.; Szymanski, J.; Perez, J.A.; Lopez, J.; Bogin, V.; Patel, A.N.; Marincola, F.M.;
Kesari, S. Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique? J. Transl. Med.
2015, 13, 1–11. [CrossRef]
101. Miyazawa, M.; Ohsawa, R.; Tsunoda, T.; Hirono, S.; Kawai, M.; Tani, M.; Nakamura, Y.; Yamaue, H. Phase I
clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination
with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010, 101, 433–439. [CrossRef]
[PubMed]
102. Okamoto, I.; Arao, T.; Miyazaki, M.; Satoh, T.; Okamoto, K.; Tsunoda, T.; Nishio, K.; Nakagawa, K. Clinical
phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients
with advanced solid tumors. Cancer Sci. 2012, 103, 2135–2138. [CrossRef] [PubMed]
103. Hayashi, H.; Kurata, T.; Fujisaka, Y.; Kawakami, H.; Tanaka, K.; Okabe, T.; Takeda, M.; Satoh, T.; Yoshida, K.;
Tsunoda, T.; et al. Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth
factor receptor 1 in solid tumor. Cancer Sci. 2013, 104, 98–104. [CrossRef] [PubMed]
104. Suzuki, H.; Fukuhara, M.; Yamaura, T.; Mutoh, S.; Okabe, N.; Yaginuma, H.; Hasegawa, T.; Yonechi, A.;
Osugi, J.; Hoshino, M.; et al. Multiple therapeutic peptide vaccines consisting of combined novel cancer
testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J. Transl. Med. 2013,
11, 1–10. [CrossRef] [PubMed]
105. Garcia Verdecia, B.; Neninger, E.; De La Torre, A.; Leonard, I.; Martínez, R.; Viada, C.; González, G.;
Mazorra, Z.; Lage, A.; Crombet, T. Effective inhibition of the epidermal growth factor/epidermal growth
factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced
non-small-cell lung cancer patients treated with the epidermal growth factor. Clin. Cancer Res. 2008, 14,
840–846. [CrossRef]
106. Tanaka, M.; Tsuno, N.H.; Fujii, T.; Todo, T.; Saito, N.; Takahashi, K. Human umbilical vein endothelial cell
vaccine therapy in patients with recurrent glioblastoma. Cancer Sci. 2013, 104, 200–205. [CrossRef]
107. Ichim, T.E.; Li, S.; Ma, H.; Yurova, Y.V.; Szymanski, J.S.; Patel, A.N.; Kesari, S.; Min, W.P.; Wagner, S.C.
Induction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma
primed placental endothelial cells: ValloVaxTM. J. Transl. Med. 2015, 13, 1–9. [CrossRef]
108. Gavilondo, J.V.; Hernández-Bernal, F.; Ayala-Ávila, M.; de la Torre, A.V.; de la Torre, J.; Morera-Díaz, Y.;
Bequet-Romero, M.; Sánchez, J.; Valenzuela, C.M.; Martín, Y.; et al. Specific active immunotherapy with a
VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation
phase I clinical trial. Vaccine 2014, 32, 2241–2250. [CrossRef]
109. Tian, L.; Goldstein, A.; Wang, H.; Ching Lo, H.; Sun Kim, I.; Welte, T.; Sheng, K.; Dobrolecki, L.E.;
Zhang, X.; Putluri, N.; et al. Mutual Regulation of Tumour Vessel Normalization and Immunostimulatory
Reprogramming. Nature 2017, 544, 250–254. [CrossRef]
110. Yuan, F.; Chen, Y.; Dellian, M.; Safabakhsh, N.; Ferrara, N.; Jain, R.K. Time-dependent vascular regression
and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial
growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA 1996, 93, 14765–14770.
[CrossRef]
111. Arjaans, M.; Schröder, C.P.; Oosting, S.F.; Dafni, U.; Kleibeuker, J.E.; De Vries, E.G.E. VEGF pathway targeting
agents, vessel normalization and tumor drug uptake: From bench to bedside. Oncotarget 2016, 7, 21247–21258.
[CrossRef]
112. Ribatti, D.; Annese, T.; Ruggieri, S.; Tamma, R.; Crivellato, E. Limitations of Anti-Angiogenic Treatment of
Tumors. Transl. Oncol. 2019, 12, 981–986. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 6180 16 of 16
113. Huang, Y.; Yuan, J.; Righi, E.; Kamoun, W.S.; Ancukiewicz, M.; Nezivar, J.; Santosuosso, M.; Martin, J.D.;
Martin, M.R.; Vianello, F.; et al. Vascular normalizing doses of antiangiogenic treatment reprogram the
immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. USA
2012, 109, 17561–17566. [CrossRef]
114. Serini, G.; Bussolino, F.; Maione, F.; Giraudo, E. Class 3 semaphorins: Physiological vascular normalizing
agents for anti-cancer therapy. J. Intern. Med. 2013, 273, 138–155. [CrossRef]
115. Maione, F.; Molla, F.; Meda, C.; Latini, R.; Zentilin, L.; Giacca, M.; Seano, G.; Serini, G.; Bussolino, F.; Giraudo, E.
Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor
vasculature in transgenic mouse models. J. Clin Invest. 2009, 119, 3356–3372. [CrossRef]
116. Shigeta, K.; Datta, M.; Hato, T.; Kitahara, S.; Chen, I.X.; Matsui, A.; Kikuchi, H.; Mamessier, E.; Aoki, S.;
Ramjiawan, R.R.; et al. Dual PD –1 and VEGFR —2 blockade promotes vascular normalization and enhances
anti–tumor immune responses in HCC. Hepatology 2019, 0–2. [CrossRef]
117. Huang, Y.; Goel, S.; Duda, D.G.; Fukumura, D.; Jain, R.K. Vascular normalization as an emerging strategy to
enhance cancer immunotherapy. Cancer Res. 2013, 73, 2943–2948. [CrossRef]
118. Schmittnaegel, M.; Rigamonti, N.; Kadioglu, E.; Cassará, A.; Rmili, C.W.; Kiialainen, A.; Kienast, Y.;
Mueller, H.J.; Ooi, C.H.; Laoui, D.; et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor
immunity that is enhanced by PD-1 checkpoint blockade. Sci. Transl. Med. 2017, 9, 9670. [CrossRef]
119. Allen, E.; Jabouille, A.; Rivera, L.B.; Lodewijckx, I.; Missiaen, R.; Steri, V.; Feyen, K.; Tawney, J.; Hanahan, D.;
Michael, I.P.; et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through
HEV formation. Sci. Transl. Med. 2017, 12, 385–413. [CrossRef]
120. Fan, Y. Vascular Detransformation for Cancer Therapy. Trends in Cancer 2019, 5, 1–4. [CrossRef]
121. Platel, V.; Faure, S.; Corre, I.; Clere, N. Endothelial-to-Mesenchymal Transition (EndoMT): Roles in
Tumorigenesis, Metastatic Extravasation and Therapy Resistance. J. Oncol. 2019, 2019, 1–13. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
